Video
PDS implant matches monthly injections in efficacy in DME treatment
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Luxa Biotechnology presents data from phase 1/2a clinical trial evaluating RPESC-RPE-4W
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2
Winners of best poster presentation award at EnVision Summit 2025